Ehlers-Danlos Syndrome

What is Ehlers-Danlos Syndrome?

Ehlers-Danlos Syndrome (EDS) is a rare group of inherited connective tissue disorders that affect the production and structure of collagen, a protein that provides strength and elasticity to skin, joints, blood vessels, and organs. The condition primarily affects the skin, joints, and blood vessels, causing symptoms ranging from joint hypermobility and skin fragility to life-threatening vascular complications. EDS comprises 14 distinct subtypes, with Classical, Hypermobile, and Vascular types being the most common. This complex condition affects an estimated 1 in 5,000 to 1 in 20,000 people worldwide, though many cases remain undiagnosed due to its variable presentation and lack of awareness among healthcare providers.

Key statistics

Symptoms

Common symptoms include joint hypermobility, skin hyperextensibility, tissue fragility, easy bruising, chronic pain, fatigue, and delayed wound healing.

The symptoms of Ehlers-Danlos Syndrome vary significantly depending on the subtype but generally affect three main areas: joints, skin, and blood vessels. Joint-related symptoms include hypermobility (joints that bend beyond normal range), frequent dislocations and subluxations, chronic joint pain, and early-onset arthritis. Skin manifestations include hyperextensibility (stretchy skin), velvety texture, fragility leading to easy tearing, poor wound healing with atrophic scarring, and easy bruising even from minor trauma.

Systemic symptoms often include chronic fatigue, muscle weakness, and pain that can be debilitating. The vascular type presents the most serious symptoms, including fragile blood vessels prone to rupture, organ fragility, and characteristic facial features such as thin nose, thin lips, and prominent eyes. Gastrointestinal symptoms may include gastroparesis, chronic constipation, and intestinal fragility. Many patients also experience autonomic dysfunction, including postural orthostatic tachycardia syndrome (POTS), which causes rapid heart rate changes with position.

Submit Your Paper

Causes and risk factors

Ehlers-Danlos Syndrome is caused by genetic mutations that affect collagen production or processing. Different subtypes involve mutations in different genes, including COL5A1 and COL5A2 (Classical type), COL3A1 (Vascular type), and TNXB (Classical-like type). The Hypermobile type’s genetic basis remains largely unknown, though recent research has identified some potential genes.

The primary risk factor is having a parent with EDS, as most types follow an autosomal dominant inheritance pattern, meaning only one copy of the mutated gene is needed to cause the condition. Some rarer types follow autosomal recessive inheritance. Family history of unexplained joint problems, skin fragility, or sudden cardiac or vascular events may indicate increased risk. Environmental factors do not cause EDS, but trauma, surgery, or pregnancy can worsen symptoms or trigger complications in those with the condition.

Prevention

Currently, there is no known way to prevent Ehlers-Danlos Syndrome. However, early detection through genetic screening and carrier testing can help families make informed decisions. Genetic counseling is recommended for individuals with a family history of EDS or unexplained connective tissue symptoms. Preimplantation genetic diagnosis may be available for some types when specific mutations are identified. For those already diagnosed, preventing complications involves avoiding high-impact activities, protecting joints through appropriate exercise and bracing, and maintaining awareness of vascular risks in applicable subtypes.

Complications

Without proper management, EDS can lead to severe complications that significantly impact quality of life and, in some cases, can be life-threatening. Joint complications include progressive joint degeneration, chronic pain, frequent dislocations requiring repeated medical intervention, and secondary osteoarthritis at a young age.

Cardiovascular complications vary by type but may include aortic root dilatation, mitral valve prolapse, and in the vascular type, arterial rupture or dissection that can be fatal. Gastrointestinal complications include bowel perforation, particularly in the vascular type, chronic gastroparesis, and severe constipation. Pregnancy complications can include preterm labor, cervical insufficiency, and increased bleeding risk.

Chronic pain and fatigue often lead to depression, anxiety, and social isolation. Sleep disturbances are common due to pain and joint instability. Many patients experience progressive disability that affects their ability to work or attend school regularly.

Diagnosis

Diagnosing Ehlers-Danlos Syndrome requires a comprehensive clinical evaluation using the 2017 International Classification criteria. The diagnostic process begins with detailed medical and family history, followed by physical examination focusing on joint hypermobility using the Beighton score, skin assessment for hyperextensibility and texture, and evaluation of other systemic features.

Genetic testing is available for most EDS subtypes and can confirm diagnosis when clinical criteria are met. For Classical type, testing focuses on COL5A1 and COL5A2 genes. Vascular type testing examines the COL3A1 gene and may include biochemical analysis of type III collagen. Currently, no genetic test exists for Hypermobile EDS, making clinical diagnosis essential.

Additional tests may include echocardiography to assess heart valve function and aortic dimensions, ophthalmologic examination for lens dislocation or retinal detachment, and specialized imaging studies if vascular complications are suspected. Skin biopsy with electron microscopy may be used in research settings but is not routinely recommended for diagnosis.

Treatment

Treatment for Ehlers-Danlos Syndrome is primarily supportive and focuses on symptom management and complication prevention. No cure currently exists, and treatment approaches are tailored to individual symptoms and EDS subtype.

Pain management often requires a multimodal approach including physical therapy, low-impact exercise programs, and medications such as acetaminophen, tramadol, or other analgesics. Joint protection involves bracing, taping, and assistive devices to prevent dislocations and reduce injury risk.

Physical therapy emphasizing muscle strengthening and proprioceptive training is crucial for joint stability. Occupational therapy helps with daily living adaptations and energy conservation techniques. For cardiovascular manifestations, medications may include losartan or other angiotensin receptor blockers to reduce arterial stress, particularly in vascular type EDS.

Gastrointestinal symptoms may be managed with prokinetic agents like metoclopramide for gastroparesis, or fiber supplements and laxatives for constipation. Orthostatic intolerance often responds to increased fluid and salt intake, compression garments, and medications such as fludrocortisone or midodrine.

Prognosis

The prognosis for Ehlers-Danlos Syndrome varies significantly by subtype and individual presentation. Most people with Classical and Hypermobile types have normal life expectancy with appropriate management, though quality of life may be affected by chronic pain and joint problems. Early diagnosis and proper management can prevent many complications and improve long-term outcomes.

Vascular type EDS has a more serious prognosis, with median life expectancy of approximately 48-50 years due to risk of arterial or organ rupture. However, with careful monitoring and lifestyle modifications, some individuals live much longer. The key prognostic factors include subtype, severity of initial presentation, access to specialized care, and adherence to activity restrictions and medical management.

Functional outcomes depend largely on pain management success, joint stability maintenance, and prevention of major complications. Many individuals with EDS lead fulfilling lives with appropriate accommodations and support systems.

Quality of life

Living with Ehlers-Danlos Syndrome requires significant lifestyle adaptations but can be manageable with proper strategies. Daily activities should focus on joint protection through proper body mechanics, frequent position changes, and use of supportive devices when needed. Low-impact exercises such as swimming, water aerobics, and carefully supervised strength training help maintain muscle tone and joint stability.

Dietary considerations include adequate protein intake to support connective tissue health, vitamin C for collagen synthesis, and increased fluid and salt intake for those with orthostatic intolerance. Sleep quality can be improved with supportive mattresses, positioning pillows, and pain management strategies.

Mental health support is crucial, as chronic pain and disability can lead to depression and anxiety. Support groups, both online and in-person, provide valuable peer connections and coping strategies. Workplace and school accommodations may include flexible scheduling, ergonomic workstations, elevator access, and modified physical requirements.

Energy conservation techniques help manage fatigue, including pacing activities, prioritizing tasks, and using assistive devices to reduce physical strain. Many individuals benefit from working with occupational therapists to develop personalized adaptive strategies.

Pregnancy and fertility

Ehlers-Danlos Syndrome can significantly impact pregnancy and requires specialized obstetric care. Fertility is generally not affected, but pregnancy complications are more common, particularly in Classical and Vascular types. Risks include preterm labor, cervical insufficiency, prolonged rupture of membranes, and increased bleeding during delivery.

Genetic counseling is essential before conception to discuss inheritance risks and prenatal testing options. Most EDS types follow autosomal dominant inheritance with 50% risk of transmission to offspring. Prenatal genetic testing is available for types with known mutations.

During pregnancy, close monitoring includes regular cervical length assessments, growth scans, and cardiology follow-up if indicated. Joint pain often worsens due to increased joint laxity from pregnancy hormones. Physical therapy and supportive garments may help manage symptoms.

Delivery planning should involve anesthesiology consultation due to potential complications with regional anesthesia, including dural tears or bleeding. Many women require cesarean delivery due to tissue fragility or failure to progress.

Children

Ehlers-Danlos Syndrome in children often presents with delayed motor milestones, frequent falls, easy bruising, and complaints of growing pains or fatigue. Early recognition is important to prevent misdiagnosis and provide appropriate support.

School accommodations may include modified physical education, extra time between classes, elevator access, and ergonomic seating. Educational support for learning difficulties, which occur more frequently in children with EDS, may be necessary.

Growth and development are usually normal, though some children may have delayed motor development due to joint hypermobility and muscle weakness. Physical therapy focusing on strength and coordination is often beneficial.

Transition to adult care should begin in adolescence, with gradual transfer of responsibility for condition management to the young person. This includes education about activity restrictions, symptom monitoring, and the importance of specialized healthcare providers familiar with EDS.

When to see a doctor

Immediate medical attention is required for signs of arterial dissection or rupture, including sudden severe chest, back, or abdominal pain, particularly in those with Vascular type EDS. Other emergency symptoms include sudden severe headache, vision changes, difficulty breathing, or signs of internal bleeding.

Routine medical care should be sought for new or worsening joint pain, frequent dislocations, significant changes in fatigue levels, or new cardiovascular symptoms such as chest pain or palpitations. Regular follow-up with specialists familiar with EDS is important for monitoring and preventing complications.

Women should seek obstetric consultation before pregnancy planning, and anyone with EDS should inform all healthcare providers about their condition before procedures or surgeries due to increased risks of complications.

Regional context

GMJ welcomes contributions from regional researchers to build the evidence base for Ehlers-Danlos Syndrome in the Caucasus. Limited data exists on EDS prevalence and presentation in Georgia, Armenia, and Azerbaijan. Establishing regional registries and improving physician awareness could help identify undiagnosed cases and improve care access in these regions.

Research and clinical trials

Current research focuses on identifying genetic causes of Hypermobile EDS, developing targeted therapies for collagen disorders, and improving pain management strategies. Recent breakthroughs include better understanding of the molecular mechanisms underlying different EDS types and development of potential gene therapy approaches.

Clinical trials are investigating novel pain management approaches, cardiovascular protective therapies, and rehabilitation techniques. The drug celiprolol has shown promise in reducing vascular complications in Vascular EDS. Patients can find current trials at ClinicalTrials.gov using search terms “Ehlers-Danlos Syndrome” or specific EDS subtypes.

Frequently asked questions

Is Ehlers-Danlos Syndrome progressive?

EDS symptoms often worsen with age due to cumulative joint damage and the natural aging process affecting already compromised connective tissue. However, progression varies significantly between individuals and subtypes.

Can people with EDS participate in sports?

Low-impact activities like swimming are generally safe and beneficial. High-contact sports and activities with jumping or sudden direction changes should be avoided due to joint injury risk. Individual assessment with a knowledgeable physician is essential.

Is EDS always inherited?

While most cases are inherited, spontaneous genetic mutations can occur, resulting in EDS without family history. However, having EDS means there’s typically a 50% chance of passing it to children.

Why is EDS often misdiagnosed?

EDS symptoms overlap with many other conditions, and awareness among healthcare providers is limited. The average time from symptom onset to diagnosis is often 10-20 years, with patients frequently being labeled as hypochondriacs or having psychological problems.

Can EDS be cured?

Currently, no cure exists for EDS as it’s a genetic condition affecting collagen production. Treatment focuses on symptom management, complication prevention, and maintaining quality of life through supportive care.

Support and resources

The Ehlers-Danlos Society (ehlers-danlos.com) provides comprehensive patient education, physician resources, and support networks. Ehlers-Danlos Support UK (ehlers-danlos.org) offers regional support and advocacy. The National Organization for Rare Disorders (NORD) at rarediseases.org provides general rare disease resources.

Orphanet (orpha.net) maintains detailed medical information and lists of specialist centers worldwide. EURORDIS (eurordis.org) advocates for rare disease patients in Europe and provides policy and research updates.

Related conditions

Marfan Syndrome – Another connective tissue disorder affecting similar body systems but with different genetic causes and clinical features. Osteogenesis Imperfecta – Connective tissue disorder primarily affecting bone strength and structure. Loeys-Dietz Syndrome – Connective tissue disorder with significant cardiovascular manifestations. Postural Orthostatic Tachycardia Syndrome (POTS) – Autonomic dysfunction commonly associated with EDS, particularly Hypermobile type. Fibromyalgia – Chronic pain condition that shares symptoms with EDS and sometimes occurs concurrently.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, UpToDate, relevant EULAR/ACR/WHO guidelines. This article is for informational purposes only and does not constitute medical advice. Content licensed under CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.